Építés alatt – nem éles oldal
Belépés
Résztvevőt keresFázis nélkül

Diagnostic Assessment of Amino Acid PET/MRI in the Evaluation of Glioma and Brain Metastases

A legfontosabb adatok

Ki végzi
Norwegian University of Science and Technology
Hol
Norvégia3 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toboroz
Résztvevők
160 fő, tervezett
Kezdés
2019. nov. 25.
Várható befejezés
2027. dec. 31.
A vizsgálat típusa
Megfigyeléses, 2 csoport
A vizsgált kezelések
  • Diagnostic Amino acid PET/MRI examination
A regiszteradat frissítve
2025. június 22.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with a diffuse glioma (a type of brain tumor) or with 1-4 brain metastases (cancer that has spread to the brain). Everyone gets amino acid PET/MRI brain scans.

Életkor
Over 18 years
Nem
All sexes
A betegség stádiuma
Glioma: WHO grade II-IV diffuse glioma, low-grade, high-grade or high-grade that has come back. Treatment and a tissue sample (biopsy) must be planned. KPS >60 (able to care for self). Brain metastases: 1-4 metastases with planned surgery or stereotactic radiosurgery (focused radiation). Expected survival of at least 3 months.
Korábbi kezelés
For stereotactic radiosurgery, the original (primary) cancer must already be known. For surgery, a brain metastasis may be suspected or already diagnosed.

A részvétel fő kizáró okai

  • Pacemaker or defibrillator that cannot be used in a 3T MRI scanner
  • Unable to give informed consent, for example due to severe speech or thinking problems
  • Pregnancy or breastfeeding
  • Weight > 120 kg (265 lb)

A regiszter feltételei, szó szerint

Mind a 7 feltétel megnézéseKevesebb

Ki vehet részt

  • Inclusion criteria Glioma (LGG, HGG and recurrent HGG):; Planned treatment for WHO grade II-IV diffuse glioma; Adult patients (>18 years); Planned tissue sampling for histopathological diagnosis; KPS >60 (able to care for self)
  • Indication of surgery or stereotactic radiosurgery for 1-4 brain metastases
  • Planned surgery: Suspicion of brain metastasis or known diagnosis
  • Stereotactic surgery: Known primary cancer
  • Adult patients (>18 years)
  • Estimated survival at least 3 months after inclusion

Ki nem vehet részt

  • Exclusion criteria (Glioma and Brain Metastasis):; Pacemakers or defibrillators not compatible with 3T MRI; No ability to obtain informed consent (e.g. due to severe dysphasia or cognitive deficits); Pregnancy (pregnancy test for all women in fertile age when doubt about possible pregnancy exist); Breastfeeding; Weight > 120 kg

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

MRI is used in clinical routine for diagnosing brain tumors, but has limitations in identifying tumor grade, true tumor extension and differentiate viable tumor tissue from treatment induced changes and recurrences.

A teljes eredeti leírásKevesebb

Amino acid PET has demonstrated a great potential for defining true tumor volume, differentiate viable tumor tissue from postoperative changes or radiation necrosis, selection of biopsy site, non-invasive grading of gliomas and for treatment planning and therapy response assessment. By combining PET with MRI, the diagnostic accuracy can improve significantly for these patients. More research is however needed to compare the most promising amino acid PET tracers in patients with glioma, but also to assess the diagnostic value of amino acid PET in patients with different brain metastases, where the knowledge concerning the uptake characteristics is limited.

Three of the most promising amino acid tracers ([11C]-methyl-methionine (11C-MET), [18F] fluoro-ethyl-tyrosin (18F-FET) and anti-1-amino-3-[18F]fluorocyclobutane-1-carboxylic acid (18F-FACBC)) will be evaluated in 3 substudies in this project; WP1 Aminoacid PET/MRI in low and high grade glioma; WP2 Role of 11C-MET in high-grade glioma Gamma Knife® radiosurgery; and WP3 Amino acid PET in brain metastasis.

The main aim of the study is to improve diagnostic accuracy, histopathological tissue sampling, delineation of tumor extent and therapy response assessment in gliomas and brain metastases with amino acid PET/MRI.

A vizsgálat 2 csoportja

  • Glioma

    20 low-grade (LGG) and 40 high-grade glioma (HGG) patients will be included from the Department of Neurosurgery at St. Olavs Hospital and the Department of Neurosurgery at the University hospital of North Norway and examined with 18F-FACBC PET/MRI at baseline and 4-6 months after surgery. Furthermore, 10 of the LGG patients and 10 of the HGG patients will be examined with an additional 18F-FET PET/MRI at baseline for comparison with 18F-FACBC. 30 recurrent HGG patients will be recruited from the Department of Neurosurgery and the Department of Oncology at the Haukeland University Hospital. These patients will be examined with 11C-MET PET/MRI at treatment/baseline and 1 month after radiosurgery.

    Kezelés: Diagnostic Amino acid PET/MRI examination

  • Brain Metastases

    Patients with brain metastases (18F-FACBC: n=20, 18F-FET: n=20 and 11C-MET: n=30) will be included from the Department of Neurosurgery at St. Olavs Hospital, the Department of Neurosurgery at Haukeland University Hospital and the Department of Neurosurgery at the University hospital of North Norway, and examined with amino acid PET/MRI at baseline, 1 month after surgery/stereotactic radiosurgery (St. Olavs Hospital/UNN: Linac, Haukeland University Hospital: Gamma Knife® radiosurgery) and at suspicion of recurrence.

    Kezelés: Diagnostic Amino acid PET/MRI examination

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
Publikációk
A regiszteradat frissítve
2025. június 22.